Profile data is unavailable for this security.
About the company
Unicocell Biomed Co Ltd is mainly engaged in the research and development of new adipose stem cell drugs and the application of stem cell technology. The main products include stem cell secretin and cell testing services. The Company's current development projects are divided into human adipose-derived mesenchymal stem cells, autologous adipose stem cell transplantation and cell preparation application products. The clinical trials of human adipose-derived mesenchymal stem cells include the ELIXCYTE-CT21 clinical trial project and the ELIXCYTE-CT31 clinical trial project. Autologous adipose stem cell transplantation is used for large-area burns and difficult wound healing. The cell preparation application products include stem cell secretin, which is a conditioned medium derived from cultured stem cells, used to improve skin dullness and fine lines.
- Revenue in TWD (TTM)19.04m
- Net income in TWD-108.55m
- Incorporated2018
- Employees--
- LocationUnicocell Biomed Co Ltd6F, No.65, Lane 77Xing-ai Road, Neihu District.TAIPEI 114TaiwanTWN
- Phone+886 227922699
- Fax+886 227927890
- Websitehttps://www.unicocell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Energenesis Biomedical Co Ltd | 6.78m | -199.00m | 3.86bn | -- | -- | 5.31 | -- | 569.04 | -2.61 | -2.61 | 0.0891 | 9.53 | 0.008 | 2.69 | 7.84 | -- | -23.36 | -25.02 | -24.32 | -25.78 | 73.90 | 69.19 | -2,936.00 | -2,619.68 | 26.74 | -- | 0.0112 | -- | -2.63 | 9.01 | 1.99 | -- | -20.91 | -- |
| Unicocell Biomed Co Ltd | 19.04m | -108.55m | 4.34bn | -- | -- | 6.03 | -- | 227.88 | -1.94 | -1.94 | 0.3395 | 12.32 | 0.0247 | 1.25 | 17.87 | -- | -14.06 | -24.25 | -14.42 | -25.60 | 66.09 | 69.89 | -570.24 | -705.40 | 29.58 | -- | 0.0902 | -- | 70.79 | 34.96 | 7.73 | -- | 9.00 | -- |
| Pell Bio Med Technology Co Ltd | 17.99m | -403.74m | 5.16bn | -- | -- | 3.76 | -- | 286.69 | -8.02 | -8.02 | 0.341 | 23.77 | 0.0132 | 10.43 | 4.23 | -- | -29.90 | -- | -34.86 | -- | -113.22 | -- | -2,262.16 | -- | 7.19 | -- | 0.0985 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
